Reduced DPP9 levels sensitize experimental breast tumors to combinatory treatment with irradiation and Olaparib - Takeaways - MDSpire

Reduced DPP9 levels sensitize experimental breast tumors to combinatory treatment with irradiation and Olaparib

  • By

  • Lisa Heß

  • Jule Koch

  • Finja Göttsche

  • Thomas Reinheckel

  • June 10, 2026

Share

  • 1

    Reduced expression of DPP9 is linked to poor prognosis in triple-negative breast cancer (TNBC) patients.

  • 2

    DPP9 deficiency in experimental models leads to increased tumor weight and metastasis in TNBC.

  • 3

    Irradiation reduces tumor growth initially, but DPP9-deficient tumors exhibit faster regrowth and more metastases.

  • 4

    Combining irradiation with the PARP inhibitor Olaparib significantly reduces tumor growth in DPP9-deficient tumors.

  • 5

    DPP9 deficiency enhances sensitivity of TNBC tumors to combined irradiation and Olaparib therapy.

Original Source(s)

Reduced DPP9 levels sensitize experimental breast tumors to combinatory treatment with irradiation and Olaparib

  • by Lisa Heß, Jule Koch, Finja Göttsche, Thomas Reinheckel

  • June 10, 2026

Related Content

Improving Empiric Antibiotic Selection for Patients With Cancer Hospitalized With Infection: Secondary

Predicting 5-Year Mortality in Non–Small-Cell Lung Cancer Using the Korean Central Cancer Registry: Model Development and Validation Study

Heroes in motion – a six-year quality report and patient evaluation of a real-world exercise therapy program in pediatric oncology